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tionally, increased tissue expression of PlGF by IHC was seen
in skin biopsies of aGVHD, while GI aGVHD tissue demon-
strated pathologically low PlGF expression. To our knowl-
edge, these results provide the ﬁrst evidence of altered
circulating and tissue expression of PlGF occurring in the HCT
setting. Studies are ongoing to determine the role of PlGF in
neovascularization and tissue repair in aGVHD, and on the
direct angiogenic and immune regulatory effect of PlGF in
HCT.433
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Umbilical cord blood (UCB) is an alternative option for he-
matopoietic stem cell transplantation and it has been suc-
cessfully used to treat children with malignant and non
malignant diseases. The slower rate of neutrophil engraft-
ment and delayed immune reconstitution impose a sub-
stantial risk for infections and mortality. Furthermore, the
use of anti-thymocyte globulin (ATG) has been linked to a
higher risk of viral infections. In order to assess the occur-
rence of viral infections we retrospectively analyzed the
outcomes of 156 children who underwent a UCB transplant
(UCBT) between January 1996 and October 2012 in a single
institution. Diagnostic methods varied over time: initially
antigenemia, immunoﬂuorescence and immunoenzymatic
tests were used and since 2005 Polymerase Chain Reaction
(PCR) was employed for vigilance and diagnosis of viral
reactivation. Fifty-one girls and 105 boys with a median age
of 60 months (range 2 e 168 months) were transplanted for
malignant (48 pts) and non-malignant diseases: BM failure
syndromes: 55 patients (pts), primary immunodeﬁciencies
(PID): 41 pts and inborn errors of metabolism (IEM): 12 pts.
HLA compatibility: 6/6 or 5/6: 98 pts and 4/6: 58 pts. Con-
ditioning Regimen was based on chemotherapy in 119 pts
and TBI based in 37 pts. The median number of Total
Nucleated Cell was 5.2 x 107/Kg (range: 1.4 - 36.4 x 107/Kg).
One hundred and forty-three pts were evaluable for
engraftment with a median time for neutrophil recovery of
26 days and for platelet recovery of 42 days. Viral infection
occurred in 99/156 pts. In the univariate analysis it was more
frequent in pts who received ATG: 87/122 (p 0.0001), in
those who developed acute GVHD: 65/80 (p 0.0001) or
chronic GVHD: 49/59 (p 0.0001) and in 4/6 HLA mismatched
UCBT (p 0.001). The most frequent virus detected in this
cohort was Cytomegalovirus (CMV): 74 pts, followed by
Epstein-Barr virus (EBV): 14 pts and adenovirus: 8pts. CMV
status pre-transplant correlated with higher incidence of
CMV infection post transplant. Moreover, viral infections
were associated with bacterial infection in 79/127 pts
(p 0.01). Death occurred in 81 pts and the main cause wasbacterial infection. In this analysis the presence of viral
infection per se was not associated with a high mortality.
Conclusion: We observed a high prevalence of viral in-
fections among UCB recipients and a positive association of
its occurrence with HLA-mismatch, development of acute or
chronic GVHD and the use of ATG. Viral infections were
usually associated with other infectious agents such bacteria
or fungi and this could be an important factor for morbidity
and mortality. Currently, close PCR surveillance allows early
detection of viremia and aggressive treatment.434
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Background: CMV recipient seropositivity (R+) is a predictor
for CMV viremia after SCT. Cytotoxic T-lymphocytes (CTL) are
critical for CMV immunity. Conventional allografts from CMV
seropositive donors (D+) confer some CMV immunity though
transfer of donor CTLs to the recipient. Thus for CMV R+, CMV
D+ are preferentially chosen over CMV D-. In contrast, ex-
vivo T-cell depleted (TCD) allografts are deﬁcient in CMV
CTLs. The effect of donor serostatus on CMV reactivation has
not been examined after TCD SCT. We studied the effect of
CMV donor serostatus on the incidence of CMV viremia in a
cohort of adult CMV R+, TCD SCT monitored by CMV PCR and
treated preemptively.
Methods: CMV R+ adults with hematologic malignancies
who received peripheral blood CD34+ selected allografts
after myeloablative conditioning regimens from March 1,
2010 through May 2013 were monitored prospectively by
CMV PCR at least weekly from day (d) +14 through +100 and
at least once every 2 weeks through d +180. Preemptive
therapy was initiated for CMV viremia, deﬁned as  1 posi-
tive PCR value. There was no CMV prophylaxis during the
study period. Follow up was through May 31, 2014. Time-
dependent Cox-proportional hazard model of univariate and
multivariate stepwise selection analyses were performed to
identify predictors of CMV viremia.
Results: Of 113 CMV R+ (median age 57.6 years, 22.5-73.0),
60 (53%) had acute leukemia, 23 (20%) myelodysplastic
syndrome, 18 (16%) multiple myeloma and 12 (11%) other.
Donors were 48 (42%) matched-related (MRD), 45 (40%)
matched unrelated (MUD), or 20 (18%)mismatched; 68 (60%)
CMV D+ or 45 (40%) D-. The cumulative incidence of CMV
viremia at 6 months was 79%. Time to onset of viremia was
median 26 days (13-83) after SCT, and time to resolution of
viremia a median 30.5 days from onset of viremia. The inci-
dence of CMV viremia was higher in R+/D+ compared to R+/
D- (90.5% versus 62.2%; P<0.0001). Median time to onset and
to resolution for R+/D+ vs R+/D- were not signiﬁcantly
different. In multivariable analysis, R+/D- pts were at lower
risk for CMV viremia compared to R+/D+ (HR: 0.57, 95% CI:
0.36-0.90; P¼0.017). In contrast, multiple myeloma (HR:
2.22, 95% CI: 1.24-3.98; P¼0.008) was associated with
increased risk compared with acute leukemia. Having a
mismatched donor was also associated with increased risk
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and (HR: 2.30, 95% CI: 1.26-4.21; P¼0.007) with MUD.
Conclusions: 1) Among CMV R+ TCD recipients, the inci-
dence of CMV viremia was 79%. 2) In multivariate analysis,
CMV D- with decreased risk for CMV viremia compared to
D+. 3) Diagnosis of multiple myeloma and allografts from
mismatched donor was associated with increased risk. 4)
Further studies are needed to assess the effect of CMV
donor serostatus in transplant outcomes in TCD. If vali-
dated in larger cohorts, our ﬁndings have implications for
donor selection and targeted strategies for CMV pre-
vention.435
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Background: Fulminant disseminated toxoplasmosis (FTX)
is a rare complication of allogeneic SCT with an incidence
ranging from 1-8% based on endemicity. Plasma quantita-
tive PCR (qPCR) affords rapid diagnosis. Before 2011, pa-
tients (pts) at MSK received pre-SCT TMP/SMZ (T/S) for
Pneumocystis (PCP) prophylaxis (ppx). Pts with positive (+)
toxo IgG (R+) or from + donors (D+) received Atovaquone
(ATQ) ppx starting day (d) 30-50 post SCT. The incidence of
toxoplasmosis was 0-1 cases/year. In 2011, T/S ppx pre-SCT
was limited to pts at high risk for PCP. From January
through June 2013 we observed a cluster of 4 cases of FTX.
Since July 2013, we have, therefore, implemented “aggres-
sive” ppx.
Methods: We compared the incidence of FTX in adult re-
cipients of peripheral blood CD34+ selected (TCD) or CB al-
lografts for hematologic malignancies from May 2012
through June 2013 (Period A) and from July 2013 through
August 2014 (Period B). R+ includes positive or equivocal
toxo IgG. PPX: In Period A, R+ or D+ received ATQ ppx starting
on d +30-50 post-SCT with no routine qPCR monitoring. In
Period B “aggressive” ppx consisted of T/S pre-SCT and ATQ
starting on d +14. qPCR was checked at least weekly from d+
14 to 60 and as needed thereafter. In Periods A and B, qPCR
was ordered in symptomatic pts at clinician’s discretion. FTX
cases are deﬁned as positive qPCR with fulminant course and
no alternative explanation.
Results: During Period A, 154 (114 TCD, 40 CB) pts had SCT
including 19 (12.3%) R+. During Period B, 144 (118 TCD, 26
CB) pts had a SCT including 20 (13.9%) R+. In Period A, 4/
154 (2.6%) pts had FTX vs. 0/144 (0%) pts in Period B. In
period A, 3/19 (15.8%) R+ and 1 R-/D- pt had FTX. R+ cases
came from Turkey, Ukraine and West Africa, received TCD
(2) or CB (1) transplants from D- (3) for acute leukemia (2)
or multiple myeloma (1) and were diagnosed <60 days
post SCT. The fourth case was R-/D-, presented 5 months
after TCD SCT, after traveling to UK and Mexico. Three pts
presented with high fevers and 1 with multi-system
deterioration. All pts progressed to multi-organ failure and
expired within 7 days of presentation. At death qPCR
ranged 0.3-5.0x106 copies/ml. No autopsies were done. Aninvestigation for a shared nosocomial source was unre-
vealing. During Period B, 1/20 (5%) R+ had 2 positive qPCRs.
This pt was asymptomatic and noncompliant with ATQ
ppx. He was treated with T/S and subsequent PCRs were
negative. The diagnostic yield of qPCR was 0.76% (2 posi-
tives out of 264 qPCR performed).
Conclusions: 1) Toxoplasmosis infection should be imme-
diately considered in sero-positive TCD and CB SCT pts pre-
senting with fevers of unknown source. 2) We advocate early
and aggressive ppx in seropositive patients. 3) Routine
monitoring with qPCR should be strongly considered if
noncompliance or suboptimal absorption with ppx is sus-
pected. 4) Optimal preventive strategies for toxoplasmosis
have to be determined for each Center based on the patient
population.436
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Background/Aim: Low serum vitamin D levels are becoming
increasingly implicated in infections, pulmonary disorders,
cancer incidence and autoimmune conditions. Their role
in allogeneic hematopoietic stem cell transplantation
(alloHSCT) remains unclear, with some studies showing
deﬁciency to be associated with lower overall survival (OS)
and increased graft versus host disease (GVHD) rates, while
other studies show no differences in OS or GVHD rates. We
investigated the relationship between low vitamin D levels
pre-alloHSCT and post-transplant outcomes (OS, progres-
sion-free survival [PFS], non-relapse mortality [NRM],
relapse and acute and chronic GVHD).
Methods: We reviewed 492 alloHSCT recipients who had
pre-transplant vitamin D results available. Data on dates of
death, last follow-up, disease progression/relapse, disease
risk index (DRI) and acute and chronic GVHD status were
collected. Patients were categorized as replete (25-OH-Vit D
 50nmol/L or on replacement therapy) or deﬁcient (25-OH-
Vit D < 50nmol/L). Subgroup analysis was performed on B-
cell non-Hodgkin lymphoma patients (B-NHL).
Results: The vitamin D-deﬁcient cohort had a higher mor-
tality rate compared to the replete group. This reduction in
survival was maintained in the multivariate analysis (HR 1.5,
95% CI 1.1-2.0, P¼0.013). There were no signiﬁcant differ-
ences in NRM, PFS, acute/chronic GVHD, or relapse rates
between the two groups. No signiﬁcant differences were
noted with any of these outcomes in the 123 B-NHL patients.
There was no association between 25-OH-Vit D levels and
DRI.
Conclusion: Vitamin D deﬁciency appears associated with
increased mortality in alloHSCT recipients. The mechanisms
of this ﬁnding remain unclear. GVHD rates did not appear to
be affected by deﬁciency. Further research looking at
whether immunomodulatory effects of vitamin D are
responsible for the survival differences noted in our study,
and previously reported studies, is required.
